Research programme: PDGF inhibitors - Seattle Life SciencesAlternative Names: PDGF antagonists; Platelet derived growth factor inhibitors
Latest Information Update: 10 Sep 2010
At a glance
- Originator ZymoGenetics
- Developer Seattle Life Sciences
- Mechanism of Action Platelet-derived growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Sep 2010 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 05 May 2009 Preclinical trials in Undefined indication in USA (unspecified route)